Okami Medical Announces FDA 510(k) Clearance of the LOBO-7 and LOBO-9 Vascular Occluders To Address A Wide Range Of Peripheral Embolization Cases

Aliso Viejo, CA – June 7, 2022 – Okami Medical Inc., a medical device company focused on developing innovative solutions that address key unmet clinical needs in peripheral vascular intervention, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the LOBO-7 and LOBO-9 Vascular Occluders, the latest addition to the company’s LOBO® Vascular Occlusion System.

Okami Medical Announces First Patients Treated With The LOBO Vascular Occluder

ALISO VIEJO, CA, March 5, 2020 — Okami Medical Inc., a medical device company, announced today the successful completion of the first cases with the LOBO™   Vascular Occlusion System. The first offering in the company’s product portfolio, LOBO-3, recently received 510(k) clearance from the U.S. Food and Drug Administration for the occlusion of peripheral arteries.

Inceptus Announces Completion of Series B Financing for Okami Medical

Inceptus Medical LLC, a medical device company incubator, announced today that it has completed a $4.5M Series B financing for Okami Medical Inc. The financing will provide the resources to develop and commercialize innovative devices for the interventional treatment of cardiovascular disease. The financing was led by members of the board of directors, U.S. Venture Partners (USVP) and medical device industry veterans.

2019© Okami Medical